Evidence map›Paper›PMID 25944154›Full record

ArticleJournal of epidemiology and global health2015

First and second line drug resistance among treatment naïve pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi.

Vithal Prasad Myneedu, Ritu Singhal, Khalid Umer Khayyam, Prem Prakash Sharma, Manpreet Bhalla, Digamber Behera, Rohit Sarin

Open access · goldAbstract read
In one paragraph

Article in Journal of epidemiology and global health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. First Line Anti-TB Drug Resistance in an Urban Area of Odisha, India.Journal of clinical and diagnostic research : JCDR · 2016
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vithal Prasad MyneeduNational Reference Laboratory & WHO Center of Excellence (Tuberculosis), Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India. Electronic address: tbmicro@gmail.com.
Ritu SinghalNational Reference Laboratory & WHO Center of Excellence (Tuberculosis), Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India. Electronic address: ritugo@hotmail.com.
Khalid Umer KhayyamDepartment of Epidemiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India. Electronic address: dr.khaliduk@yahoo.com.
Prem Prakash SharmaDepartment of Statistics, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India. Electronic address: ppsharma@hotmail.com.
Manpreet BhallaNational Reference Laboratory & WHO Center of Excellence (Tuberculosis), Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India. Electronic address: mnprtbhalla@yahoo.com.
Digamber BeheraDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India. Electronic address: dirlrsi@gmail.com.
Rohit SarinDepartment of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India. Electronic address: tbmicro@gmail.com.
LRS Institute of Tuberculosis and Respiratory Diseases · INPost Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is limited information of level of drug resistance to first-line and second line anti-tuberculosis agents in treatment naïve pulmonary tuberculosis (PTB) patients from the Indian region. Therefore, the present prospective study was conducted to determine the antimicrobial susceptibility to first-line and second line anti-TB drug resistance in such patients. Sputum samples from consecutive treatment naïve PTB cases registered in Lala Ram Sarup (LRS) district, under RNTCP containing 12 Directly Observed Treatment Centre's (DOTS), were enrolled using cluster sampling technology. A total of 453 samples were received from July 2011 to June 2012. All samples were cultured on solid medium followed by drug susceptibility to first and second line anti-tubercular drugs as per RNTCP guidelines. Primary multi-drug resistance (MDR) was found to be 18/453; (4.0%). Extensively drug resistance (XDR) was found in one strain (0.2%), which was found to be resistant to other antibiotics. Data of drug resistant tuberculosis among treatment naïve TB patients are lacking in India. The presence of XDR-TB and high MDR-TB in small population studied, calls for conducting systematic multi-centric surveillance across the country.

Indexed as

AdolescentAdultAgedAged, 80 and overAntitubercular AgentsChildExtensively Drug-Resistant TuberculosisFemaleHumansIndiaMaleMiddle AgedMycobacterium tuberculosisProspective StudiesSputumTuberculosis, Multidrug-ResistantAntitubercular AgentsAntibioticExtensively drug resistanceMulti-drug resistancePrimaryPulmonary

Identifiers

PMID25944154
PMCPMC7320499
OpenAlexW2149413522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.